Material Agreement, Private Placement (Form 8-K)

On September 3, 2026 and September 4, 2026, AIM ImmunoTech Inc. (the "Company") entered into a total of two exchange agreements (the "Exchange Agreements") and, for each, a corresponding partitioned promissory note (together, the "Partitioned Promissory Notes") with Streeterville Capital, LLC (the "Lender") related to that certain Promissory Note dated November 18, 2025 (the "Promissory Note"). Pursuant to the Exchange Agreements and Partitioned Promissory Notes, the Company and the Lender converted approximately $450,000 of the Promissory Note into 1,921,441 shares (the "Exchange Shares") of the Company's common stock, at an average conversion price of approximately $0.234 per share.

The Company's stockholders previously approved the conversion or other satisfaction of the Promissory Note, pursuant to NYSE American Company Guide Sections 713(a) and 713(b), at a special meeting of stockholders held on July 15, 2026.

The foregoing descriptions of the Exchange Agreements and Partitioned Promissory Notes are qualified in their entirety by reference to the full text of the form of the Exchange Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

The Exchange Shares were or will be issued pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended, provided by Section 3(a)(9) thereof as securities exchanged by the Company with its existing security holder exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange.